Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Current Deferred Revenue (2023 - 2024)

Spruce Biosciences (SPRB) has disclosed Current Deferred Revenue for 2 consecutive years, with $697000.0 as the latest value for Q3 2024.

  • Quarterly Current Deferred Revenue fell 91.06% to $697000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $697000.0 through Sep 2024, down 91.06% year-over-year, with the annual reading at $4.9 million for FY2023, N/A changed from the prior year.
  • Current Deferred Revenue for Q3 2024 was $697000.0 at Spruce Biosciences, down from $1.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $13.0 million in Q1 2023, with the low at $697000.0 in Q3 2024.